The miniaturization, sophistication, proliferation, and accessibility of technologies are enabling the capturing of more and previously inaccessible phenomena in Parkinson disease (PD). However, more information has not translated into greater understanding of disease complexity to satisfy diagnostic and therapeutic needs. Challenges include non-compatible technology platforms, the need for wide-scale and long-term deployment of sensor technology (in particular among vulnerable elderly patients), and the gap between the “big data” acquired with sensitive measurement technologies and their limited clinical application. Major opportunities could be realized if new technologies are developed as part of open-source and/or open-hardware platforms enabling multi-channel data capture, sensitive to the broad range of motor and non-motor problems that characterize PD, and adaptable into self-adjusting, individualized treatment delivery systems. The International Parkinson and Movement Disorders Society Task Force on Technology is entrusted to convene engineers, clinicians, researchers, and patients to promote the development of integrated measurement and closed-loop therapeutic systems with high patient adherence that also serve to: 1) encourage the adoption of clinico-pathophysiologic phenotyping and early detection of critical disease milestones; 2) enhance tailoring of symptomatic therapy; 3) improve subgroup targeting of patients for future testing of disease modifying treatments; and 4) identify objective biomarkers to improve longitudinal tracking of impairments in clinical care and research. This article summarizes the work carried out by the Task Force toward identifying challenges and opportunities in the development of technologies with potential for improving the clinical management and quality of life of individuals with PD.
38000F19ure 1. 6ene5 and pr0m0ter5 1n the k c11 9ene re910n. 5h0wn 15 800 6p 0f x DNA 1n rever5e 0f the 5tandard repre5entat10n, extend1n9 fr0m p051t10n 38,800 (num6ered acc0rd1n9 t0 Dan1e15 et a1. 1983) t0 p051t10n 38,000, and 1nc1ud1n9 the cr0 and c119ene5 and the 5• end 0f the 0 9ene. 7ran5cr1pt10n fr0m pR re5u1t5 1n expre5510n 0f the cr0, c11, 0, and 0ther d0wn5tream 9ene5. 7ran5cr1pt10n fr0m pR~ 15 act1vated 6y the c11 pr0te1n and re5u1t51n an ant15en5e cr0 tran5cr1pt and expre5510n 0f the c1 and rex 9ene5 (10cated at the r19ht 0f the f19ure). 7ran5cr1pt10n fr0m P0 re5u1t51n the 77-6a5e 00P RNA tran5cr1pt, term1nat1n9 at the t 0 term1nat0r 51te. [F0r a m0re c0mp1ete d15cu5510n 0f tran5cr1pt10na1 c0ntr015 1n th15 re910n, 5ee Her5k0w1t2 and Ha9en (1980);Wu1ff and R05en6er9 (1983); Ech015 (1986)1. dem0n5trated prev10u51y. 00P RNA cann0t enc0de a 5h0rt p01ypept1de: N0 AU6 0r 6U6 c0d0n and n0 cha1n term1nat10n c0d0n ex15t 1n any frame 0f read1n9. Re5u1t5A mu1t1c0py 00P DNA p1a5m1d 1nh161t5 c11 expre5510n1n the mu1t1c0py p1a5m1d pKM2, a 398-6p ~ DNA fra9-ment c0nta1n1n9 the c11-dependent k PR~ pr0m0ter 15 fu5ed t0 the E. c011 9a1K 9ene and 90vern5 1t5 tran5cr1p-t10n {F1en et a1. 1984). 6a1act0k1na5e 5ynthe515 fr0m pKM2 15 act1vated 6y c11 pr0te1n, wh1ch may 6e pr0v1ded 6y a derepre55ed k pr0pha9e, pre5ent 1n 51n91e c0py 1n the h05t chr0m050me. H0wever, 1f a 515ter p1a5m1d that c0n-ta1n5 a 651-6p ~ p~ DNA fra9ment fu5ed t0 9a1K 15 5u6-5t1tuted f0r pKM2 1n th15 5y5tem, n0 9a1K expre5510n 15 065erved, a 5eem1n9 parad0x (7a61e 1). 7he 1ar9er PR£ DNA fra9ment a150 c0nta1n5 the 00P re910n, 1nc1ud1n9 the 00P pr0m0ter, w1th the var10u5 pr0m0ter and term1nat0r e1ement5 a11 0r1ented 1n the 5ame d1rect10n 1n the 0rder p0-t0-P~-9a1K (F19. 2). 7hat the parad0x re5u1t5 fr0m the 00P DNA 5e4uence 1n the 1ar9er PRE p1a5m1d 7a61e 1. 1nh161t10n 0f cH-9ene expre5510n 6y 00P DNA p1a5m1d5P1a5m1d5 6a1act0k1na5e act1v1ty (un1t5) pKM2 (pRE-9a1K) 700 pK0-5K650 (p0-00P; p~-9a1K) 6 pDw60 (p~-9a1K) + p8R322 (•00P) 670 pDw60 {pRn-9a1K) + pLK39 {p0-00P) 2Der1vat1ve5 0f E. c011 5tra1n Uc6183 (k1nt6 c1t5857 cr027 c11 + Pam3), c0nta1n1n9 the 1nd1cated mu1t1c0py p1a5m1d5, were 9r0wn t0 109 pha5e at 32°C and then 5h1fted t0 42°c t0 1nduce c119ene expre5510n fr0m the pr0pha9e. At 30-m1n, extract5 were made and 9a1act0k1na5e act1v1t1e5 determ1ned (F1en et a1. 1984). P1a5m1d 5tructure5 are d15p1ayed 1n F195.2 and 3.15 5u99e5ted 6y the f1nd1n9 that 9a1act0k1na5e expre5510n 6y the 0r191na1 pRE-9a1K p1a5m1d 15 a1m05t c0mp1ete1y 1nh161ted 6y 1ntr0duc1n9 a 5ec0nd mu1t1c0py p1a5m1d that c0nta1n5 a 150-6p k 00P DNA fra9ment (7a61e 1). 7h15 00P fra9ment extend5 fr0m 60 6p 6ef0re the 00P tran5cr1pt10n 5tart p01nt, thr0u9h the 00P 5e4uence, t0 13 6p 6ey0nd the 00P term1nat10n 51te (F19. 3). An 00P effect can a150 6e 065erved w1th0ut u51n9 the 9a1act0k1na5e a55ay 5y5tem: k + f0rm5 c1ear p1a4ue5 0n a var1ant 0f the E. c011 1nd1cat0r 5tra1n C600 that c0nta1n5 a der1vat1ve 0f the mu1t1c0py 00P DNA p1a5m1d pLK33. 00P RNA 15 the 1nh161t0ry a9ent1f the 00P DNA fra9men...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.